МАКЛИН Питер (CH),БЕРГОНЦЕЛЛИ ДЕ ГОНДА Габриела (CH),КОЛЛИНС Стивен Майкл (CA),БЕРЦИК Премисл (CA),ВЕРДЮ де БЕРЦИК Элен (CA)
申请号：
RU2012111253/15
公开号：
RU2012111253A
申请日:
2010.08.24
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. Composition containing Bifidobacterium longum ATCC BAA-999 for use in the prevention and / or treatment of functional disorders of the gastrointestinal tract. 2. The composition according to claim 1, in which the gastrointestinal functional disorder is selected from the group consisting of irritable bowel syndrome, functional dyspepsia, functional constipation, functional diarrhea, functional abdominal pain, functional bloating, epigastric pain syndrome, distress syndrome after eating, or combinations. 3. Composition according to any one of the preceding paragraphs, in which a gastrointestinal functional disorder is associated with anxiety. 4. The composition according to claim 1, selected from the group consisting of a food composition, animal feed composition, dietary supplement, nutraceutical, nutritional mixture, drink and / or medical composition. The composition according to claim 1 or 4, additionally containing at least one other type of other bacteria of the food grade, where the bacteria of the food grade are preferably selected from the group consisting of lactic acid bacteria, bifidobacteria, propionibacteria or mixtures thereof. 6. A composition according to claim 1 or 4, further comprising at least one prebiotic. The composition of claim 6, wherein the prebiotic is selected from the group consisting of oligosaccharides and optionally contains fructose, galactose, mannose, soy and / or inulin, dietary fiber, or mixtures thereof. The composition according to claim 1, wherein at least 5%, preferably at least 10%, more preferably at least 15% of the Bifidobacterium longum ATCC BAA-999 in the composition is viable. The composition of claim 1, wherein at least 80%, preferably at least 90%, more preferably1. Композиция, содержащая Bifidobacterium longum ATCC BAA-999 для использования в профилактике и/или лечении функциональных расстройств ЖКТ.2. Композиция по п.1, в которой функциональное расстройство ЖКТ выбрано из группы, состоящей из синдрома раздраженно
